In patients who undergo elective treatment for abdominal aortic aneurysm (AAA), hospital expenses required for open repair surpass the higher initial graft cost of endovascular aortic aneurysm repair ...

Surgeon classification of a patient as unfit for open repair of an abdominal aortic aneurysm (AAA) predicts higher rates of postoperative complications and reduced long-term survival following ...

Aug. 25, 2004 — Endovascular aneurysm repair (EVAR) has favorable 30-day operative mortality compared with open repair, according to the results of a randomized trial published online in The Lancet on ...

“Advancements in endograft stent technologies and a shift from open surgical repair to minimal invasive endovascular repair has led to the sizeable market growth.” The global endovascular aneurysm ...

Patients considered high risk for open aneurysm repair had a low mortality rate after endovascular aneurysm repair, despite previously reported results from the EVAR 2 trial. According to data ...

An endovascular aneurysm sealing system was associated with higher 3-year survival than traditional endovascular aneurysm repair in patients with abdominal aortic aneurysms, according to findings ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

This study evaluated the value of computed tomographic angiography (CTA) early after an endovascular aneurysm repair (EVAR) in relation to CTA 3 months after EVAR. We retrospectively reviewed all ...

EVAR trial participants (2005) Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet 365: ...

Ruptured abdominal aortic aneurysms (rAAA) are responsible for nearly 2% of all deaths in U.S. men over the age of 65. Endovascular aneurysm repair (EVAR) has emerged as a newer and less invasive ...

IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global ...